aspirin

TCT 2020 | Xience se suma a la evidencia de doble antiagregación corta en alto riesgo de sangrado

TCT 2020 | Xience in Favor of Short Dual Antiaggregation Therapy with High Bleeding Risk

Following with aspirin alone after a short period of dual antiaggregation therapy (DAPT), 1 to 3 months, did not increase ischemic events in patients receiving a Xience stent while significantly reducing bleeding.&nbsp; This study endorses the safety of short DAPT with contemporary drug eluting stents (DES) in patients presenting high bleeding risk.&nbsp; The XIENCE Short<a href="https://solaci.org/en/2020/10/21/tct-2020-xience-in-favor-of-short-dual-antiaggregation-therapy-with-high-bleeding-risk/" title="Read more" >...</a>

TCT 2020 | Administrar el comprimido de prasugrel molido previo a la angioplastia

TCT 2020 | Crushed Prasugrel Administration prior PCI

Prehospital administration of crushed tablets of prasugrel loading dose in the ambulance while patient is on his way to primary PCI does not improve reperfusion markers compared against uncrushed tablet administration according to the COMPARE CRUSH, presented at the virtual TCT 2020 and simultaneously published in Circulation. There were no differences in TIMI flow of<a href="https://solaci.org/en/2020/10/21/tct-2020-crushed-prasugrel-administration-prior-pci/" title="Read more" >...</a>

Doctor con tabletas de aspirinas

How To De-Escalate Prasugrel After Acute Coronary Syndrome?

Patients who undergo coronary angioplasty after acute coronary syndrome could de-escalate dual antiplatelet therapy with prasugrel to maintain the protection against ischemic events while lowering their hemorrhagic risk. The HOST-REDUCE-POLYTECH-ACS study (recently published in The Lancet) included 2338&nbsp;patients who underwent coronary angioplasty in a setting of acute coronary syndrome. Patients were randomized to a year-long<a href="https://solaci.org/en/2020/10/21/how-to-de-escalate-prasugrel-after-acute-coronary-syndrome/" title="Read more" >...</a>

The Most Read Articles of September in Interventional Cardiology

01- ESC 2020 | New European Guidelines on Non-ST-Segment Elevation Acute Coronary Syndromes: What’s New? The new European guidelines on NON-ST-segment elevation acute coronary syndromes (NSTE ACS) were presented virtually during the European Society of Cardiology 2020 Congress (ESC&nbsp;2020) and published in&nbsp;Eur Heart J. Read more HERE 02- Ticagrelor to Improve Venous Graft Patency Saphenous<a href="https://solaci.org/en/2020/10/09/the-most-read-articles-of-september-in-interventional-cardiology/" title="Read more" >...</a>

Post TAVR ASA Monotherapy Consolidates

This meta-analysis to be published in J Am Cardiol supports the use of aspirin monotherapy (ASA) after transcatheter aortic valve replacement (TAVR). The use of aspirin alone is associated to less bleeding without increased ischemic events such as strokes or mortality.&nbsp; The combined outcomes of four studies, including the recently published POPular TAVI (cohort A),<a href="https://solaci.org/en/2020/10/07/post-tavr-asa-monotherapy-consolidates/" title="Read more" >...</a>

THEMIS: eventos isquémicos y hemorrágicos en difícil equilibrio para el ticagrelor crónico

Ticagrelor to Improve Venous Graft Patency

Saphenous vein graft patency is one of CABG’s “Achilles heals”, especially after the ARTS trial came out showing bilateral internal mammary artery grafting was not superior to simple internal mammary artery grafting.&nbsp; Antiaggregation more potent than aspirin might prolong venous graft patency in cases when the available techniques will fail to improve poor outcomes.&nbsp;&nbsp;&nbsp; Previous<a href="https://solaci.org/en/2020/09/18/ticagrelor-to-improve-venous-graft-patency/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Evidence or Theory? Antiaggregation Scheme after Peripheral Vascular Intervention

Antiaggregation indication after peripheral intervention (PVI) can vary up to 50% depending on center, operator, and procedure.&nbsp; This highlights the huge variation in indication and the scarce evidence there is on this matter.&nbsp; Most cardiologists would like to simply transfer the information from the coronaries to the superficial femoral, but we can confirm this does<a href="https://solaci.org/en/2020/09/15/evidence-or-theory-antiaggregation-scheme-after-peripheral-vascular-intervention/" title="Read more" >...</a>

ESC 2020 | El Rivaroxaban puede reducir los eventos cardíacos, cerebrales y periféricos

ESC 2020 | Rivaroxaban Might Reduce Cardiac Cerebral and Peripheral Events

Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in patients with peripheral vascular disease undergoing revascularization.&nbsp;&nbsp; These new data resulted from the analysis of the VOYAGER PAD subgroups and were presented at the virtual ESC 2020. The COMPASS study had reached similar conclusions using 2.5 mg rivaroxaban<a href="https://solaci.org/en/2020/09/09/esc-2020-rivaroxaban-might-reduce-cardiac-cerebral-and-peripheral-events/" title="Read more" >...</a>

ESC 2020 | Against the Grain, ASA Monotherapy Appears Superior after TAVR

After TAVR, patients with no anticoagulation indication are favored by monotherapy with aspirin (ASA) vs. dual antiaggregation therapy (DAPT).&nbsp; This study presented at ESC 2020, simultaneously published in NEJM, seems to go against the latest “fashion” (P2Y12 inhibitor monotherapy) and randomized patients to ASA monotherapy vs. DAPT with clopidogrel for 3 months. Unlike with the<a href="https://solaci.org/en/2020/09/03/esc-2020-against-the-grain-asa-monotherapy-appears-superior-after-tavr/" title="Read more" >...</a>

ESC 2020 | Guías de Fibrilación Auricular 2020: Novedades sobre diagnóstico, clasificación y tratamiento

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and symptoms. Mavacamten is the first myosin inhibitor drug of its class. Presented virtually at the European Society of Cardiology 2020 Congress (ESC&nbsp;2020) and published simultaneously in The Lancet, the EXPLORER-HCM study showed that 37% of patients who received<a href="https://solaci.org/en/2020/09/03/esc-2020-new-drug-improves-functional-capacity-in-hypertrophic-cardiomyopathy/" title="Read more" >...</a>

Top